SIWA Therapeutics Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 4
Employees
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $6.37M
Latest Deal Amount

SIWA Therapeutics General Information

Description

Operator of a pre-clinical stage company intended to emphases on a monoclonal antibody that targets and destroys cancerous cells. The company's first-in-class humanized monoclonal antibody ("mAb"), SIWA 318H, selectively targets both senescent cells ("SCs") and cancer cells for destruction by the immune system. It's In vivo results shows SIWA 318M (a SIWA 318H mouse homolog) reduces SCs in normally-aged, very old mice and reduces cancer metastasis lung foci (triple-negative breast cancer model). It can become the first comprehensive cancer therapy as it uniquely reduces cancer cells as well as the SCs surrounding the cancer cells in the tumor micro-environment that stimulate, feed, and protect them.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Drug Discovery
Discovery Tools (Healthcare)
Primary Office
  • 400 East Randolph Street
  • Suite 705
  • Chicago, IL 60601
  • United States
+1 (312) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

SIWA Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 13-Aug-2019 $6.37M 000 Completed Pre-Clinical Trials
2. Angel (individual) 22-May-2017 00.000 00.000 Completed Pre-Clinical Trials
1. Capitalization 01-Jan-2011 Completed Startup
To view SIWA Therapeutics’s complete valuation and funding history, request access »

SIWA Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Lewis Gruber Co-Founder, Board Member, Chief Scientific Officer & Chief Executive Officer
Misty Gruber Co-Founder & Chief Administrative Officer
Gabriela Rossi Chief Research Officer
To view SIWA Therapeutics’s complete executive team members history, request access »

SIWA Therapeutics Board Members (4)

Name Representing Role Since
Alex Kormushoff SIWA Therapeutics Board Member 000 0000
Jim Alvarez SIWA Therapeutics Board Member 000 0000
John Peters III SIWA Therapeutics Chairman 000 0000
Lewis Gruber SIWA Therapeutics Co-Founder, Board Member, Chief Scientific Officer & Chief Executive Officer 000 0000
To view SIWA Therapeutics’s complete board members history, request access »

SIWA Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial